Losartan in Decompensated Heart Failure

Status Completed

Clinical Trial Summary

The dual blockade of the renin-angiotensin-aldosterone system with an angiotensin-converting enzyme inhibitor and an angiotensin-receptor blocker used together in heart failure patients has been demonstrated to be beneficial. However, the dual inhibition has not been studied during heart failure decompensation or even when low cardiac output is present.

The objective of this study was to assess the effects of add-on therapy with angiotensin receptor blocker on plasma B-type natriuretic peptide levels and hemodynamic measurements in heart failure patients with low cardiac output during hospitalization for decompensation.

This was a randomized, double-blind, placebo-controlled clinical trial.

Clinical Trial Description

The inclusion criteria were hospitalization for decompensated heart failure defined by worsening of symptoms until fatigue or dyspnea at rest, low cardiac output defined by the clinical-hemodynamic profile, dobutamine dependence, and ejection fraction < 0.45, spontaneous breathing and receiving angiotensin-converting enzyme inhibitors. The patients could have jugular ingurgitation, lower limbs edema, ascites and rales. Dobutamine dependence was defined by infusion for more than 15 days or an unsuccessful attempt of withdrawal.

The exclusion criteria were serum creatinine > 3.0 mg/dL, serum potassium > 6.0 mEq/L, systolic blood pressure < 70 mm Hg, aortic stenosis, and acute coronary syndrome in the previous 2 months. The patients were randomly assigned by permuted block of 4, stratified by sex, to losartan or placebo.

The endpoints were change in B-type natriuretic peptide levels, cardiac index, pulmonary wedge capillary pressure, systemic vascular resistance, and successful withdrawal of dobutamine. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01857999
Study type	Interventional
Source	InCor Heart Institute
Contact
Status	Completed
Phase	Phase 4
Start date	September 2008
Completion date	March 2011

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04115735` - His Bundle Recording From Subclavian Vein
Recruiting	`NCT05562037` - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA	N/A
Completed	`NCT05563701` - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting	`NCT05865184` - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed	`NCT04037436` - Functional Exercise and Nutrition Education Program for Older Adults	N/A
Recruiting	`NCT04703842` - Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction	Phase 1/Phase 2
Terminated	`NCT05594940` - Heart Failure Monitoring With a Portable Ultrasound Device With Artificial Intelligence Assisted Tools: A Multi-Phase Observational Feasibility Study
Recruiting	`NCT04982081` - Treating Congestive HF With hiPSC-CMs Through Endocardial Injection	Phase 1
Completed	`NCT04394754` - Evaluating Efficacy of Digital Health Technology in the Treatment of Congestive Heart Failure	N/A
Active, not recruiting	`NCT01385176` - Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)	N/A
Not yet recruiting	`NCT05516290` - Evaluating Clinical Trial Experiences of Individuals With Congestive Heart Failure
Terminated	`NCT02788656` - Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)	Phase 4
Completed	`NCT02885636` - Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial	Phase 3
Completed	`NCT02252757` - Assess Measurements of Wireless Cardiac Output Device	N/A
Terminated	`NCT02205411` - Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation	N/A
Completed	`NCT01362855` - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Withdrawn	`NCT00346177` - Stem Cell Study for Patients With Heart Failure	Phase 2
Active, not recruiting	`NCT01058837` - SCD-HeFT 10 Year Follow-up	N/A
Completed	`NCT00957541` - Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.